Zacks: Brokerages Anticipate Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Will Announce Quarterly Sales of $4.27 Billion

Analysts expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to post sales of $4.27 billion for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $4.20 billion to $4.32 billion. Teva Pharmaceutical Industries posted sales of $4.70 billion in the same quarter last year, which suggests a negative year-over-year growth rate of 9.1%. The firm is expected to announce its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that Teva Pharmaceutical Industries will report full year sales of $17.18 billion for the current financial year, with estimates ranging from $17.06 billion to $17.43 billion. For the next year, analysts anticipate that the company will post sales of $17.13 billion, with estimates ranging from $16.73 billion to $17.76 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.02. The business had revenue of $4.30 billion during the quarter, compared to analyst estimates of $4.38 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.84% and a negative net margin of 18.66%. Teva Pharmaceutical Industries’s quarterly revenue was down 15.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.94 EPS.

A number of equities research analysts recently commented on TEVA shares. Oppenheimer raised Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $12.00 price target for the company in a research report on Monday, June 3rd. Cantor Fitzgerald raised their target price on Teva Pharmaceutical Industries from $16.00 to $25.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Bank of America lowered Teva Pharmaceutical Industries from a “buy” rating to an “underperform” rating and decreased their target price for the company from $19.00 to $9.00 in a research report on Thursday, May 30th. Wells Fargo & Co reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Friday, May 10th. Finally, CIBC raised Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $12.00 target price for the company in a research report on Monday, June 3rd. Five investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries has an average rating of “Hold” and an average price target of $16.00.

NYSE TEVA traded down $0.01 on Friday, reaching $8.80. The company had a trading volume of 207,421 shares, compared to its average volume of 22,527,716. The stock has a market capitalization of $8.96 billion, a PE ratio of 3.15, a P/E/G ratio of 0.99 and a beta of 1.64. The business has a fifty day moving average price of $10.28. Teva Pharmaceutical Industries has a 52-week low of $7.96 and a 52-week high of $25.96. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.66.

In related news, Director Sol J. Barer bought 111,000 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was acquired at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the purchase, the director now directly owns 115,942 shares in the company, valued at $1,041,159.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Notaristefani Carlo De sold 16,070 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $11.42, for a total value of $183,519.40. Following the completion of the transaction, the vice president now owns 49,659 shares of the company’s stock, valued at approximately $567,105.78. The disclosure for this sale can be found here. Company insiders own 0.49% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. boosted its stake in Teva Pharmaceutical Industries by 4.0% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 19,861 shares of the company’s stock worth $311,000 after purchasing an additional 767 shares during the period. ARK Investment Management LLC boosted its position in shares of Teva Pharmaceutical Industries by 3.6% during the 1st quarter. ARK Investment Management LLC now owns 24,462 shares of the company’s stock valued at $384,000 after acquiring an additional 856 shares during the last quarter. Hancock Whitney Corp boosted its position in shares of Teva Pharmaceutical Industries by 7.8% during the 4th quarter. Hancock Whitney Corp now owns 12,056 shares of the company’s stock valued at $186,000 after acquiring an additional 868 shares during the last quarter. Lindbrook Capital LLC boosted its position in shares of Teva Pharmaceutical Industries by 61.2% during the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after acquiring an additional 945 shares during the last quarter. Finally, Wedbush Securities Inc. boosted its position in shares of Teva Pharmaceutical Industries by 3.7% during the 1st quarter. Wedbush Securities Inc. now owns 28,385 shares of the company’s stock valued at $445,000 after acquiring an additional 1,015 shares during the last quarter. Institutional investors and hedge funds own 65.08% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply